OTCMKTS:WDBG

Woodbrook Group Competitors

$1.60
0.00 (0.00 %)
(As of 04/19/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.60
Now: $1.60
$1.60
50-Day Range
$1.00
MA: $1.41
$2.00
52-Week Range
$0.15
Now: $1.60
$4.00
Volume1 shs
Average Volume961 shs
Market Capitalization$223,986.00
P/E RatioN/A
Dividend YieldN/A
Beta-2.24

Competitors

Woodbrook Group (OTCMKTS:WDBG) Vs. ATRX, ANTH, PXYN, SPHS, ARGSQ, and SNNAQ

Should you be buying WDBG stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Woodbrook Group, including Adhera Therapeutics (ATRX), Anthera Pharmaceuticals (ANTH), Praxsyn (PXYN), Sophiris Bio (SPHS), Argos Therapeutics (ARGSQ), and Sienna Biopharmaceuticals (SNNAQ).

Woodbrook Group (OTCMKTS:WDBG) and Adhera Therapeutics (OTCMKTS:ATRX) are both small-cap finance companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, earnings, risk and dividends.

Profitability

This table compares Woodbrook Group and Adhera Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Woodbrook GroupN/AN/AN/A
Adhera TherapeuticsN/AN/A-3,131.56%

Earnings and Valuation

This table compares Woodbrook Group and Adhera Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Woodbrook GroupN/AN/AN/AN/AN/A
Adhera Therapeutics$250,000.003.14$-11,980,000.00N/AN/A

Woodbrook Group has higher earnings, but lower revenue than Adhera Therapeutics.

Analyst Ratings

This is a summary of current ratings and recommmendations for Woodbrook Group and Adhera Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Woodbrook Group0000N/A
Adhera Therapeutics0000N/A

Volatility and Risk

Woodbrook Group has a beta of -2.24, suggesting that its share price is 324% less volatile than the S&P 500. Comparatively, Adhera Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the S&P 500.

Summary

Adhera Therapeutics beats Woodbrook Group on 2 of the 3 factors compared between the two stocks.

Anthera Pharmaceuticals (OTCMKTS:ANTH) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability and analyst recommendations.

Risk & Volatility

Anthera Pharmaceuticals has a beta of 2.19, indicating that its stock price is 119% more volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, indicating that its stock price is 324% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Anthera Pharmaceuticals and Woodbrook Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Anthera Pharmaceuticals0000N/A
Woodbrook Group0000N/A

Profitability

This table compares Anthera Pharmaceuticals and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Anthera PharmaceuticalsN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Valuation & Earnings

This table compares Anthera Pharmaceuticals and Woodbrook Group's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Anthera PharmaceuticalsN/AN/AN/AN/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Summary

Anthera Pharmaceuticals beats Woodbrook Group on 1 of the 1 factors compared between the two stocks.

Praxsyn (OTCMKTS:PXYN) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, risk, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Praxsyn and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PraxsynN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Analyst Ratings

This is a summary of recent ratings and price targets for Praxsyn and Woodbrook Group, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Praxsyn0000N/A
Woodbrook Group0000N/A

Earnings and Valuation

This table compares Praxsyn and Woodbrook Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PraxsynN/AN/AN/AN/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Volatility and Risk

Praxsyn has a beta of -1.34, indicating that its share price is 234% less volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, indicating that its share price is 324% less volatile than the S&P 500.

Summary

Praxsyn beats Woodbrook Group on 1 of the 1 factors compared between the two stocks.

Sophiris Bio (OTCMKTS:SPHS) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, valuation, profitability and analyst recommendations.

Profitability

This table compares Sophiris Bio and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sophiris BioN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Volatility & Risk

Sophiris Bio has a beta of 1.86, meaning that its stock price is 86% more volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, meaning that its stock price is 324% less volatile than the S&P 500.

Earnings and Valuation

This table compares Sophiris Bio and Woodbrook Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sophiris BioN/AN/A$-6,780,000.00N/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Analyst Recommendations

This is a summary of current recommendations and price targets for Sophiris Bio and Woodbrook Group, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sophiris Bio0000N/A
Woodbrook Group0000N/A

Summary

Sophiris Bio beats Woodbrook Group on 1 of the 1 factors compared between the two stocks.

Argos Therapeutics (OTCMKTS:ARGSQ) and Woodbrook Group (OTCMKTS:WDBG) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Analyst Ratings

This is a summary of current ratings for Argos Therapeutics and Woodbrook Group, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Argos Therapeutics0000N/A
Woodbrook Group0000N/A

Valuation and Earnings

This table compares Argos Therapeutics and Woodbrook Group's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Argos Therapeutics$1.90 million0.30$-40,570,000.00N/AN/A
Woodbrook GroupN/AN/AN/AN/AN/A

Woodbrook Group has lower revenue, but higher earnings than Argos Therapeutics.

Risk & Volatility

Argos Therapeutics has a beta of 2.47, suggesting that its share price is 147% more volatile than the S&P 500. Comparatively, Woodbrook Group has a beta of -2.24, suggesting that its share price is 324% less volatile than the S&P 500.

Profitability

This table compares Argos Therapeutics and Woodbrook Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Argos TherapeuticsN/AN/AN/A
Woodbrook GroupN/AN/AN/A

Summary

Argos Therapeutics beats Woodbrook Group on 2 of the 2 factors compared between the two stocks.

Woodbrook Group (OTCMKTS:WDBG) and Sienna Biopharmaceuticals (OTCMKTS:SNNAQ) are both small-cap finance companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability and dividends.

Volatility and Risk

Woodbrook Group has a beta of -2.24, indicating that its share price is 324% less volatile than the S&P 500. Comparatively, Sienna Biopharmaceuticals has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Woodbrook Group and Sienna Biopharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Woodbrook Group0000N/A
Sienna Biopharmaceuticals0000N/A

Profitability

This table compares Woodbrook Group and Sienna Biopharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Woodbrook GroupN/AN/AN/A
Sienna BiopharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares Woodbrook Group and Sienna Biopharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Woodbrook GroupN/AN/AN/AN/AN/A
Sienna BiopharmaceuticalsN/AN/A$-73,470,000.00N/AN/A

Summary

Sienna Biopharmaceuticals beats Woodbrook Group on 1 of the 1 factors compared between the two stocks.


Woodbrook Group Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ATRX
Adhera Therapeutics
0.0$0.07flat$872,000.00$250,000.000.00Gap Up
Anthera Pharmaceuticals logo
ANTH
Anthera Pharmaceuticals
0.5$0.06flat$865,000.00N/A0.00
PXYN
Praxsyn
0.6$0.00flat$763,000.00N/A0.00
SPHS
Sophiris Bio
0.1$0.02flat$739,000.00N/A0.00Gap Down
Argos Therapeutics logo
ARGSQ
Argos Therapeutics
0.6$0.05flat$572,000.00$1.90 million0.00
Sienna Biopharmaceuticals logo
SNNAQ
Sienna Biopharmaceuticals
0.5$0.03flat$547,000.00N/A0.00
TRPXD
Therapix Biosciences
0.0$9.20flat$460,000.00N/A0.00High Trading Volume
BSPM
Biostar Pharmaceuticals
0.0$0.15flat$399,000.00N/A0.00
SKVI
Skinvisible
0.7$0.08flat$376,000.00$40,000.000.00
EPRSQ
EPIRUS Biopharmaceuticals
0.5$0.02flat$366,000.00N/A0.00
Spotlight Innovation logo
STLT
Spotlight Innovation
0.5$0.01flat$343,000.00N/A0.00
ProMetic Life Sciences logo
PFSCF
ProMetic Life Sciences
0.5$5.47flat$338,000.00$36.55 million0.00Gap Up
ROSGQ
Rosetta Genomics
0.0$0.10flat$183,000.00N/A0.00Gap Down
PZRXQ
PhaseRx
0.2$0.02flat$175,000.00N/A0.00
OREXQ
Orexigen Therapeutics
0.4$0.01flat$100,000.00$33.71 million0.00Gap Up
MetaStat logo
MTST
MetaStat
0.0$0.01flat$82,000.00$20,000.000.00
AXMP
AXM Pharma
0.2$0.00flat$81,000.00N/A0.00
ALSE
Alseres Pharmaceuticals
0.0$6.00flat$36,000.00N/A0.00
BOPH
Bohai Pharmaceuticals Group
0.5$0.00flat$20,000.00N/A0.00
Immune Therapeutics logo
IMUN
Immune Therapeutics
0.6$0.01flat$7,000.00$110,000.000.00Gap Up
Acusphere logo
ACUS
Acusphere
0.0$0.04flat$0.00N/A0.00Gap Down
Affymax logo
AFFY
Affymax
0.6$0.10flat$0.00N/A0.00Gap Up
AOBI
American Oriental Bioengineering
0.4$1.50flat$0.00N/A0.00
ARYX
ARYx Therapeutics
0.0$0.01flat$0.00N/A0.00
AHROQ
AtheroNova
0.0$0.01flat$0.00N/A0.00
CBPI
China Botanic Pharmaceutical
0.0$0.07flat$0.00N/A0.00
China Dongsheng International logo
CDSG
China Dongsheng International
0.3$0.01flat$0.00N/A0.00
China Health Industries logo
CHHE
China Health Industries
0.4$0.49flat$0.00$9.93 million8.13
DDXSQ
Diadexus
0.0N/AN/A$0.00N/A0.00
ERBA
ERBA Diagnostics
0.8$0.04flat$0.00N/A0.00
FTCY
Global Future City
0.5$0.00flat$0.00N/A0.00
GLSI
Greenwich LifeSciences
2.0$32.68flat$0.00N/A0.00Decrease in Short Interest
Gap Up
HRBR
Harbor Diversified
0.0$1.28flat$0.00$263.61 million0.00
IPAH
Interpharm
0.2$0.00flat$0.00N/A0.00
IRBS
IR Biosciences
0.0$0.00flat$0.00N/A0.00High Trading Volume
MBVXQ
MabVax Therapeutics
0.0$0.02flat$0.00N/A0.00Gap Up
MYRX
Myrexis
0.5$0.06flat$0.00N/A0.00Gap Up
NNBP
Nanobac Pharmaceuticals
0.0$0.00flat$0.00N/A0.00Gap Down
PARD
Poniard Pharmaceuticals
0.5$0.05flat$0.00N/A0.00Gap Up
SGTI
Shengtai Pharmaceutical
0.2$0.02flat$0.00N/A0.00
SKBI
Skystar Bio-Pharmaceutical
0.5$0.00flat$0.00N/A0.00
SUWN
Sunwin Stevia International
0.5$0.06flat$0.00$26.09 million0.00Gap Down
Sycamore Entertainment Group logo
SEGI
Sycamore Entertainment Group
0.3$0.04flat$0.00N/A0.00
SYNI
Synvista Therapeutics
0.0$0.00flat$0.00N/A0.00
Targeted Medical Pharma logo
TRGM
Targeted Medical Pharma
0.8$0.07flat$0.00N/A0.00
TPIY
Tianyin Pharmaceutical
0.6$0.00flat$0.00N/A0.00High Trading Volume
Tibet Pharmaceuticals logo
TBET
Tibet Pharmaceuticals
0.0$0.03flat$0.00N/A0.00Gap Down
VOQP
VioQuest Pharmaceuticals
0.0$0.02flat$0.00N/A0.00
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.